Sonographic Study of Female Pelvic Organs in Breast Cancer Patients Taking Tamoxifen: Clinical Correlation

Rafia Parveen¹, Shaik Shofiu Rahman², Taposhi Sarker³, Syed Muhammad Baqui Billah⁴, Zakir Hossain Habib⁵

¹Associate Professor, Department of Radiology & Imaging, Delta Medical College & Hospital, Dhaka, Bangladesh; ²Professor & Head, Department of Radiology & Imaging, Delta Medical College & Hospital, Dhaka, Bangladesh; ³Assistant Professor, Department of Radiology & Imaging, Delta Medical College, Dhaka, Bangladesh; ⁴Assistant Professor, Department of Epidemiology, Sulaiman Al Rajhi University, Saudi Arabia; ⁵Associate Professor, Department of Microbiology, Institute of Epidemiology, Disease Control & Research (IEDCR) Dhaka, Bangladesh

[Received on: 2 October 2019; Accepted on: 1 December 2019; Published on: 1 January 2020]

Abstract

Background: As most of breast cancer patients are treated with Tamoxifen, different effects of this drug in patients should be evaluated since no such study is carried out in Bangladesh till date. Objective: The purpose of the present study was to evaluate sonographic changes of female genital organs in breast cancer patients treated with Tamoxifen and to correlate these changes with duration of Tamoxifen treatment and gynecological symptoms. Methodology: This randomized double-blind clinical trial was carried out in Delta Medical College Hospital, Dhaka, Bangladesh from May 2017 to April 2018 for a period of one (1) year. The participants were breast cancer patients which were divided into three groups named as group I patients. The patients of these group were on Tamoxifen therapy. The patients of group II were without Tamoxifen therapy. The patients of group III had completed Tamoxifen therapy. All participants underwent ultrasonography. Results: Patients receiving Tamoxifen therapy had significantly more thickened endometrium compared to other groups (26.6% in group I, 5% in group II and 3% in group III). Similarly, abnormal sonographic findings and mean uterine volume were higher in group I compared to other two groups. Endometrial thickness and uterine volume showed significant positive correlation with duration of Tamoxifen therapy (p <0.0001). The endometrial thickness and uterine volume greatly increased after two years of Tamoxifen therapy while it was reverse in group III. Gynecological symptoms had no significant relations with sonographic abnormalities and thickened endometrium. Conclusion: Tamoxifen therapy is associated with increased endometrial thickness, uterine volume and abnormal sonographic findings, compared to patients without Tamoxifen or completing Tamoxifen therapy. [Journal of Current and Advance Medical Research, January 2020;7(1):17-23]

Keywords: Breast cancer; Tamoxifen; sonography; endometrium

Correspondence: Dr. Rafia Parveen, Associate Professor, Department of Radiology & Imaging, Delta Medical College & Hospital, Dhaka, Bangladesh; Email: prafia08@yahoo.com; Cell no.: +8801716605274


Funding: This research did not receive any grant from any funding agency in the public, commercial or not-for-profit sector.

Conflict of Interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Contributions to authors: Parveen R, Rahman SS, Sarker T involved in protocol preparation, data collection; statistical analysis Parveen R. Billah SMB, Habib ZH had involved in manuscript writing & revision of the manuscript.

Copyright: ©2020. Parveen et al. Published by Journal of Current and Advance Medical Research. This article is published under the Creative Commons CC BY-NC License (https://creativecommons.org/licenses/by-nc/4.0/). This license permits use, distribution and reproduction in any medium, provided the original work is properly cited, and is not used for commercial purposes.
Introduction

Breast cancer is the most common cancer in women with worldwide high incidence including Bangladesh. According to global cancer statistics, more than 2 million new breast cancer cases were diagnosed. Tamoxifen is a selective non-steroidal estrogen receptor modulator that is commonly used as adjuvant therapy in the treatment of primary and metastatic breast cancer and prevention of breast cancer in high-risk women.

The drug shows anti-oestrogenic activity on breast and oestrogenic effects on uterus, ovaries, bone, liver and cardiovascular system. Tamoxifen may cause endometrial thickening, endometrial hyperplasia, increased uterine volume, endometrial polyps, increase in the size of uterine leiomyomata, endometriosis, ovarian cysts. The most serious adverse effect of Tamoxifen is risks of developing endometrial cancer and uterine sarcoma.

Reports suggest that the risk, incidence and severity of endometrial cancer increases with dose and duration of Tamoxifen therapy. Ashraf et al. studied adverse effects of Tamoxifen on 3,000 Indian women. Hot flashes, fatty infiltration of liver, mild vaginal dryness, vaginal discharge and vaginal bleeding were seen in some patients. A good proportion of asymptomatic patients had a thickened endometrium.

Vosse et al. conducted a study on 3 groups of postmenopausal women. Group I comprised of breast cancer patients on Tamoxifen, group II had breast cancer patients without Tamoxifen intake and group III had women without breast cancer or Tamoxifen therapy. Initial mean endometrial thicknesses were 8.2 mm in group I, 4.4 mm in group II and 3.4 mm in group III. Endometrial lesions were most common in Tamoxifen group. A significant association was observed between endometrial pathologies and both cumulated dose and total duration of Tamoxifen therapy. Polyps were the most frequent pathology. 5 cancers were detected in group I, all of whom had taken Tamoxifen for more than 3 years.

American College of Obstetricians and Gynecologists recommend that women taking Tamoxifen should be informed about the risks of Tamoxifen use including endometrial cancer. Any abnormal vaginal bleeding, bloody vaginal discharge, staining or spotting in these patients should be investigated. Periodic monitoring should be done, when indicated.

Methodology

This was a randomized, double-blind clinical trial carried out in Delta Medical College Hospital, Dhaka, Bangladesh from May 2017 to April 2018 for a period of one (1) year. The study was approved by Ethical Committee of Delta Medical College Hospital. Breast cancer patients with or without undergoing Tamoxifen therapy or completed this treatment or, women who had taken hormone replacement therapy or oral contraceptives within six months and who had undergone hysterectomy were included as study population. The study included total 320 breast cancer patients who were advised pelvic sonography during their follow up visits. Among them, 154 were menstruating women and 166 were post-menopausal women. The participants were divided into 3 groups: group I (n=150, patients taking Tamoxifen tablet 20 mg per day for at least six months), group II (n=140, patients not taking Tamoxifen tablet) and group III (n=30, patients who have already completed Tamoxifen therapy). Group I patients received Tamoxifen tablet for a mean period of 29.1±6.5 months (ranging 6 months to 72 months). After taking informed written consent, all patients were asked about Tamoxifen therapy and any gynecological symptoms. Each patient had undergone transabdominal and transvaginal sonography (TVS) using Akola 500 system and Philips Affinity 50G machines. The endometrial thickness was measured on midline sagittal scan from anterior to posterior endometrium. Care was taken not to include hypoechoic myometrium or intruterine fluid in this measurement. Endometrial cysts were defined as more than one hypoechoic area greater than 1 mm in maximum diameter. Endometrial polyp was defined as protrusion into endometrium greater than 5 mm in maximum diameter. Menopause was defined as cessation of menstruation for at least 1 year. For postmenopausal and amenorrheic premenopausal women, endometrial thickening was defined as endometrial thickness >8 mm and >12 mm for women with regular menstruation. Volume of uterus was measured in all patients using the following formula: Volume= 0.5233 X length X width X AP diameter. Endometrial thickness and uterine volume was assessed with duration of
Tamoxifen treatment and gynecological symptoms. Statistical analysis was performed using the SPSS software version 23.0. The qualitative variables were assessed with the Chi-square test, while the continuous variables were assessed with t-test or ANOVA, as applicable. The distribution of duration was divided into two groups, one is ≤2 years and >2 years.

We plotted error bars to assess the relationship of treatment duration or duration after completion of treatment with endometrial thickness and uterine volume. A p value of <0.05 was considered as statistically significant.

**Result**

Age distribution of the 3 groups is shown in Table 1. The mean age of participants was 47.37±9.83 years with the range of 23 to 78 years. No association was seen between the three patient groups and the age group, though the group III patients were a bit older compared to other two (p=0.03).

<table>
<thead>
<tr>
<th>Table 1: Age Distribution of the Patients in 3 Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age Group</td>
</tr>
<tr>
<td>-----------</td>
</tr>
<tr>
<td>20 to 30 Years</td>
</tr>
<tr>
<td>31 to 40 Years</td>
</tr>
<tr>
<td>41 to 50 Years</td>
</tr>
<tr>
<td>51 to 60 Years</td>
</tr>
<tr>
<td>61 to 70 Years</td>
</tr>
<tr>
<td>71 to 80 Years</td>
</tr>
<tr>
<td>Total</td>
</tr>
<tr>
<td>Mean± SD</td>
</tr>
</tbody>
</table>

*Chi-square test was performed to see the level of significance; **Student t test was done to see the level of significance

The distribution of thickened endometrium, sonographic abnormalities and mean uterine volume of three groups of patient were recorded. Tamoxifen group (Group I) showed significant number of thickened endometrium, sonographic abnormalities and larger mean uterine volume compared to other two groups. Among total 320 patients, 10 patients (3.1%) had gynecological symptoms. Gynecological symptoms like post-menopausal bleeding, irregular period, heavy period or per-vaginal discharge were found in 7(4.7%) patients of Tamoxifen group, 2(1.4%) patients of control group and 1(3.3%) case of completed group. No significant correlation was found between gynecological symptoms in these three groups. Even there was no relation between gynecological symptoms and sonographic abnormalities.

<table>
<thead>
<tr>
<th>Table 2: Thickened Endometrium, Ultrasonography and Mean Uterine Volumes in 3 Groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Findings</td>
</tr>
<tr>
<td>----------</td>
</tr>
<tr>
<td>Thick endometrium</td>
</tr>
<tr>
<td>Sonographic abnormality</td>
</tr>
<tr>
<td>Gynecological symptoms</td>
</tr>
<tr>
<td>Mean Uterine Volume(cc)</td>
</tr>
</tbody>
</table>

Correlation of duration of Tamoxifen therapy with endometrial thickness and mean uterine volume were assessed in Tamoxifen group (Group-I) which showed statistically significant (p<0.0001 and 0.001 respectively) positive correlation.

On the other hand, there was a negative correlation of mean endometrium thickness with duration after therapy completion, though the relation was not significant.

In the same manner, the uterine volume showed no correlation with the duration after therapy completion in group III (Table 3).
Table 3: Correlation of Duration of Tamoxifen Therapy (Group I) and Duration of Therapy Completion (Group III) With Endometrial Thickness and Uterine Volume

<table>
<thead>
<tr>
<th>Dependent variable</th>
<th>Group I</th>
<th>Group III</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>r value</td>
<td>P value</td>
</tr>
<tr>
<td>Endometrial thickness</td>
<td>0.43</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Uterine volume</td>
<td>0.27</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Unique finding from the study: While we observed the change of endometrial thickness and uterine volume with group I over time, we checked the frequency and found that there was an interesting difference of changes of endometrial thickness and uterine volume before and after 2 years. We assessed these changes and found that after 2 years there was significant increase of endometrial thickness (before 7.12±2.29 mm, after 10.11±4.44 mm; p<0.001) and uterine volume (before 70.15±28.70 ml, after 86.55±40.46 ml; p=0.004). While we checked this for those who completed Tamoxifen therapy (group III) we found that there was no difference of endometrial thickness nor uterine volume, indicating that these parameters came back to normal after cessation of therapy (Figure I to IV).

Table 4 shows distribution of sonographic abnormalities in 3 groups of patients. Most frequent abnormalities were inhomogeneous endometrium, endometrial cysts and endometrial polyps.
Table 4: Abnormal Sonographic Findings in 3 groups

<table>
<thead>
<tr>
<th>Group</th>
<th>Sonographic findings</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group-I</td>
<td>Inhomogeneous Endometrium</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Endometrial cyst</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Endometrial polyp</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Adnexal cyst</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Endometrial collection</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Endometrial cyst with adnexal cyst</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Endometrial mass</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Pelvic inflammatory disease</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Bilateral adnexal masses</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Endometrial mass+adnexal cyst</td>
<td>1</td>
</tr>
<tr>
<td>Group-II</td>
<td>Endometrial cyst</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Adnexal cyst</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Pelvic inflammatory disease</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Endometrial collection</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Endometrial polyp</td>
<td>1</td>
</tr>
<tr>
<td>Group-III</td>
<td>Inhomogeneous Endometrium</td>
<td>1</td>
</tr>
</tbody>
</table>

Discussion

Many studies have shown Tamoxifen therapy in breast cancer patients is related with increased number of endometrial abnormalities. Kim et al. found pathological changes in significant number of breast cancer patients treated with Tamoxifen namely endometrial polyps, proliferative endometrium, submucosal myoma, simple hyperplasia, atrophic endometrium and ovarian cysts. Teixeira et al. found 5.8% atrophy, 29.4% polyps, 11.7% hyperplasia and 5.8% endometrial carcinoma in Tamoxifen treated patients. In present study, ultrasonographic abnormalities were found in significant number of patients on Tamoxifen therapy.

In several reports of Tamoxifen use, the most frequent Tamoxifen-induced endometrial abnormalities were polyps. In current study, the most frequent pathologies are inhomogeneous endometrium, endometrial cysts and endometrial polyps. Kalampokas et al. and Ashraf et al. found thickened endometrium in 40% and 36.6% Tamoxifen-treated patients, respectively. The present study shows thick endometrium in 26.6% patients of Tamoxifen group, 5% in control group and 3.3% in Tamoxifen completed group.

In some studies, significantly larger uterus, thicker endometrium, polyps, endometrial fluid collection and heterogeneous endometrial echotexture were found in Tamoxifen-treated women. Studies by Gupta et al., Fishman et al. and Hummelde et al. showed thickened endometrium in significant number of Tamoxifen-treated patients, their studies showed significant positive correlations between endometrial thickness and duration of Tamoxifen therapy.

We also found correlation of endometrial thickness and uterine volume with duration of Tamoxifen therapy. In study by Fishman et al., endometrial thickness increases gradually with duration of Tamoxifen therapy and decreases slowly after completion of the therapy. Menada et al. found a statistically significant reduction in endometrial thickness at 6 months after discontinuation of Tamoxifen therapy. We found a negative though non-significant correlation of endometrial thickness with duration after completion of therapy in Tamoxifen-treated patients. Study by Hann et al. on 91 post-menopausal women has shown significant increased endometrial thickness in patients on Tamoxifen for 5 years or more (14 mm compared to 5 mm in patients on Tamoxifen for less than 5 years). Our study revealed a unique finding of endometrial thickness increase of 10 mm after two years compared to 6 mm before. Including this, our study also found similar fashion of increase in uterine volume after two years in Tamoxifen group (Figure 3). These findings suggest that we need to investigate deep into the relation of Tamoxifen therapy duration and endometrial thickness or uterine volume.

Risk of endometrial cancer increases with duration of Tamoxifen therapy. In a study by Hann et al. on 91 breast cancer patients, 2 endometrial cancers were found in women who were treated with Tamoxifen for 6 years. Donne et al. found higher incidence of endometrial cancer in patients exposed to Tamoxifen for more than four years. In present study, endometrial masses developed in 2 patients who received Tamoxifen therapy for more than 3 years.

In current study, gynecological symptoms were found in 7 (4.7%) patients of Tamoxifen group, 2 (1.4%) patients of control group and 1 (3.3%) of completed group. No correlation was found between gynecological symptoms and sonographic abnormalities, similar to studies by Ozsener et al. and Hann et al. However, Teixeira et al. and Deligdisch et al. found a greater number of histological abnormalities and thickened
endometrium in symptomatic patients compared to asymptomatic ones.

**Conclusion**

Tamoxifen therapy is associated with increased endometrial thickness and high uterine volume compared to patients without or completed therapy. The increase is also related to the duration of therapy. In this study, some gynecological pathologies were found in Tamoxifen-treated breast cancer patients. The endometrial thickness decreased gradually in breast cancer patients after completion of Tamoxifen therapy. Presence or absence of gynecological symptoms was found as an unreliable sign for diagnosing endometrial changes. Thus regular pelvic sonographic monitoring of patients on Tamoxifen therapy will be helpful to detect early changes.

**References**

therapy for breast cancer: ultrasonographic, hysteroscopic and histological findings. European Journal Of Gynaecological Oncology, 2006;27(1):4